SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...

SAB Biotherapeutics Provides SAB-142 Trial Update SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes

SAB Biotherapeutics to Present at INNODIA Annual Meeting SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.